Free Trial

Rhythm Pharmaceuticals (RYTM) Competitors

Rhythm Pharmaceuticals logo
$65.14 -1.25 (-1.88%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$64.34 -0.80 (-1.22%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RYTM vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMC

Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Rhythm Pharmaceuticals vs. Its Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$130.13M31.85-$260.60M-$2.81-23.18
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64

Rhythm Pharmaceuticals presently has a consensus target price of $78.07, suggesting a potential upside of 19.85%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
3.00
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-123.26% -739.62% -44.27%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 1 mentions for Intra-Cellular Therapies. Rhythm Pharmaceuticals' average media sentiment score of 0.55 beat Intra-Cellular Therapies' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intra-Cellular Therapies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rhythm Pharmaceuticals has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Summary

Rhythm Pharmaceuticals beats Intra-Cellular Therapies on 9 of the 16 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RYTM vs. The Competition

MetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.22B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-23.1820.8026.9620.11
Price / Sales31.85286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / Book186.117.487.985.56
Net Income-$260.60M-$55.04M$3.16B$248.40M
7 Day Performance-2.66%2.44%2.39%4.67%
1 Month Performance-2.37%1.90%2.18%6.64%
1 Year Performance44.95%4.35%33.82%21.31%

Rhythm Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RYTM
Rhythm Pharmaceuticals
3.4426 of 5 stars
$65.14
-1.9%
$78.07
+19.9%
+48.9%$4.22B$130.13M-23.18140News Coverage
Analyst Forecast
ITCI
Intra-Cellular Therapies
0.7316 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
4.0028 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-16.6%$13.02B$3.12B11.662,682Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7024 of 5 stars
$15.08
flat
$16.95
+12.4%
-4.7%$12.59B$325.54B22.8527,811
MRNA
Moderna
4.3762 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-72.1%$11.79B$3.24B-3.425,800Gap Up
RGC
Regencell Bioscience
0.3808 of 5 stars
$18.43
-19.8%
N/AN/A$11.37BN/A0.0010Gap Up
High Trading Volume
VTRS
Viatris
2.6564 of 5 stars
$9.20
-1.3%
$10.40
+13.0%
-12.7%$10.94B$14.74B-2.9032,000
QGEN
QIAGEN
3.8865 of 5 stars
$47.49
-1.8%
$49.40
+4.0%
+22.3%$10.75B$1.98B119.075,765
ASND
Ascendis Pharma A/S
3.4843 of 5 stars
$175.98
+1.0%
$220.67
+25.4%
+23.2%$10.65B$393.54M-28.021,017
BBIO
BridgeBio Pharma
4.6665 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+65.2%$8.35B$221.90M-12.32400
BPMC
Blueprint Medicines
1.5098 of 5 stars
$128.40
+0.0%
$128.06
-0.3%
+10.4%$8.29B$508.82M-51.98640Insider Trade

Related Companies and Tools


This page (NASDAQ:RYTM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners